版本:
中国

BRIEF-Allergan completes acquisition of Chase Pharmaceuticals

Nov 22 Allergan Plc

* Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to alzheimer's disease

* Deal for an upfront payment of $125 million

* Allergan to advance CPC-201 into Phase 3 registration study in 2017

* Deal includes additional potential milestone payments related to chase's lead compound, CPC-201, and certain backup compounds

* Allergan plc - Allergan to advance cpc-201 into phase 3 registration study in 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐